Cost-Utility Analysis of Certolizumab Pegol Plus Methotrexate for the Treatment of Moderate-To-Severe Active Rheumatoid Arthritis In Greece
Abstract
Authors
C. Tzanetakos N. Maniadakis G. Kourlaba A. Tzioufas A. Goules T. Theodoratou P. Christou